Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

TRDA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 41.84M shares rose 1.9% year over year, behind the +5.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.9% toward the trailing-twelve-month pace of +5.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
41.84M+1.1% QoQ
Last fiscal yearDec 2025
41.37M+10.9% YoY
LTMMar 2026
41.5M+5.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.9%——
1 year+10.9%——
3-year CAGR+9.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
41.37M USD
Year-over-year change
+10.9%
4-year CAGR
+7.3%

Weighted Avg Shares vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's LTM Mar 2026 weighted avg shares of 41.5M shares is the 8th highest of the 11 companies compared; the peer median is 54.17M shares.
  • Its year-over-year change of +5.9% is the 6th highest of 11, against a peer median of +5.6%.
  • Over three fiscal years its annual growth of +9.8% compares with a peer median of +15.3%.
TRDA Competitors Peer median
Weighted Avg Shares for TRDA and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.1%+15.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 202648.09M +39.5%+60.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +5.9%+9.8%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
SGMTSagimet Biosciences Inc.LTM Mar 202632.39M +0.9%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
Peer median (excluding TRDA) 54.17M+5.6%+15.3%

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00129.01M210.78M25.42M
Cost of Revenue00004.1M
Gross Profit00129.01M210.78M21.33M
Gross Margin——100.0%100.0%83.9%
Research & Development35.93M66.61M99.88M125.31M142.27M
Selling, General & Admin15.2M30.64M32.29M38.47M41.05M
Operating Expenses51.13M97.25M132.18M163.77M177.32M
Depreciation & Amortization1.12M1.9M2.84M3.77M425K
EBITDA(50.04M)(90.09M)14.9M70.26M(142.4M)
EBITDA Margin——11.5%33.3%-560.2%
Operating Income(51.13M)(97.25M)(3.16M)47.01M(156M)
Operating Margin——-2.5%22.3%-613.7%
Interest Income02.63M15.22M19.47M0
Interest Expense02.63M000
Other Income / Expenses(31K)2.63M15.22M19.47M13.17M
Income Before Tax(51.16M)(94.62M)12.06M66.49M(142.83M)
Pre-Tax Margin——9.3%31.5%-561.8%
Income Tax Expense0018.74M859K924K
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Net Margin——-5.2%31.1%-565.5%
EPS (Basic)(1.60)(2.79)(0.20)1.76(3.47)
EPS (Diluted)(1.60)(2.79)(0.20)1.68(3.47)
Weighted Avg Shares31.22M31.29M33.05M37.31M41.37M
Weighted Avg Shares (Diluted)31.22M31.29M33.05M39M41.37M

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$5.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.